Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
July 6, 2009
- Alogliptin Approval to Be Delayed at Least 2 Years: Takeda
July 6, 2009
- REGULATORY NEWS IN BRIEF
July 6, 2009
- Sandoz's Growth Hormone Approved as Japan's First Biosimilar
July 6, 2009
- JSGM Proposes Free Pricing System for Generics
July 6, 2009
- R&D NEWS IN BRIEF
June 29, 2009
- Injectable Risperdal to Change Treatment of Schizophrenia: Janssen
June 29, 2009
- Japan Participates in Multinational PIII Study of JAK-3 Inhibitor: Pfizer
June 29, 2009
- Eli Lilly Japan to Increase Sales of Anticancer Drugs to 30% of Total Sales
June 29, 2009
- Top Quark to Create New CRO to Undertake Asian Trials
June 29, 2009
- Glufast, Urief to Drive Kissei's Growth: Dr Ajisawa
June 29, 2009
- Asahi Kasei Medical: Planova BioEX
June 29, 2009
- Sales of Class 1 OTC Drugs Down Following Full Implementation of Amended PAL: JACDS
June 29, 2009
- REGULATORY NEWS IN BRIEF
June 29, 2009
- JACDS Approves Tadayuki Teranishi as New President
June 29, 2009
- DSUR (E2F) Fails to Reach Step 4 in Yokohama: ICH
June 29, 2009
- SELF-MEDICATION NEWS IN BRIEF
June 29, 2009
- Various Intellectual Properties Should Be Used for Lifecycle Management: Prof. Yamana
June 29, 2009
- OPINION／High Price for Executive Search in Japan
June 29, 2009
- Patents on New DDS Formulations with Known API, Indications May Become Eligible for Patent Period Restoration
June 29, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…